Evidence map›Paper›PMID 29206243›Full record

ArticleFrontiers in pharmacology2017

Corrigendum: Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice.

Wei Chen, Fengchun Shui, Cheng Liu, Xinbo Zhou, Wei Li, Zhibing Zheng, Wei Fu, Lili Wang

Abstract readPublished Erratum
In one paragraph

Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Journal of Cancer · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Wei ChenBeijing Institute of Pharmacology and Toxicology, Beijing, China.
Fengchun ShuiBeijing Institute of Pharmacology and Toxicology, Beijing, China.
Cheng LiuDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, China.
Xinbo ZhouBeijing Institute of Pharmacology and Toxicology, Beijing, China.
Wei LiBeijing Institute of Pharmacology and Toxicology, Beijing, China.
Zhibing ZhengBeijing Institute of Pharmacology and Toxicology, Beijing, China.
Wei FuDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, China.
Lili WangBeijing Institute of Pharmacology and Toxicology, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article on p. 707 in vol. 8, PMID: 29051736.].

Indexed as

blood–brain-barrierCB1R antagonistobesityperiphery

Identifiers

PMID29206243
PMCPMC5712340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.